The role of complement in the development and manifestation of murine atherogenic inflammation: Novel avenues

Journal of Innate Immunity

Volumn 4, Issue 3, 2012, Pages 260-272

  Francescut, Lorenza ^a   Steiner, Tanja ^b   Byrne, Simon ^a   Cianflone, Katherine ^c   Francis, Sheila ^b   Stover, Cordula ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c LAVAL UNIVERSITY   (Canada)

Author keywords

Atherosclerosis; Complement; Mouse models

Indexed keywords

CD59 ANTIGEN; CHOLESTEROL; COMPLEMENT; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C5; COMPLEMENT COMPONENT C5A; COMPLEMENT COMPONENT C6; COMPLEMENT COMPONENT C9; DECAY ACCELERATING FACTOR; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 18; MACROPHAGE MIGRATION INHIBITION FACTOR; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; ADIPOSE TISSUE; ARTERY WALL; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BACTERIAL INFECTION; BLOOD CLOTTING; CHRONIC INFLAMMATION; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT CLASSICAL PATHWAY; CYTOKINE PRODUCTION; DISEASE EXACERBATION; EXPERIMENTAL MODEL; HUMAN; INFLAMMATION; INNATE IMMUNITY; LIPID STORAGE; MACROPHAGE; MORBIDITY; MORTALITY; MOUSE; NONHUMAN; OBESITY; PHENOTYPE; PRIORITY JOURNAL; REVIEW; THROMBOCYTE FUNCTION; THROMBOGENESIS;

ADIPOSE TISSUE; ANIMALS; ATHEROSCLEROSIS; BLOOD COAGULATION; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM PROTEINS; DISEASE MODELS, ANIMAL; HUMANS; IMMUNITY, INNATE; INFLAMMATION MEDIATORS; MACROPHAGES; MICE; MICE, KNOCKOUT;

EID: 84859924300     PISSN: 1662811X     EISSN: 16628128     Source Type: Journal    
DOI: 10.1159/000332435     Document Type: Review

References (88)

1. Staprans I, Pan XM, Rapp JH, Grunfeld C, Feingold KR: Oxidized cholesterol in the diet accelerates the development of atherosclerosis in LDL receptor-and apolipoprotein Edeficient mice. Arterioscler Thromb Vasc Biol 2000; 20: 708-714. (Pubitemid 30151685)
2. Horie S, Hiraishi S, Hirata Y, Kazama M, Matsuda J: Oxidized low-density lipoprotein impairs the anti-coagulant function of tissuefactor-pathway inhibitor through oxidative modification by its high association and accelerated degradation in cultured human endothelial cells. Biochem J 2000; 352: 277-285. (Pubitemid 32011422)
3. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R; Cholesterol Treatment Trialists' (CTT) Collaborators: Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-1278.
4. Ko YG, Kim BK, Lee BK, Kang WC, Choi SH, Kim SW, Lee JH, Lee M, Honda Y, Fitzerald PJ, Shim WH; SECURE Investigators: Study design and rationale of 'Synergistic effect of combination therapy with cilostazol and ProbUcol on plaque stabilization and lesion REgression (SECURE)' study: A doubleblind randomised controlled multicenter clinical trial. Trials 2011; 12: 10.
5. Koenen RR, Weber C: Therapeutic targeting of chemokine interactions in atherosclerosis. Nat Rev Drug Discov 2010; 9: 141-153.
6. Ricklin D, Hajishengallis G, Yang K, Lambris JD: Complement: A key system for immune surveillance and homeostasis. Nat Immunol 2010; 11: 785-797.
7. Alving CR, Richards RL, Guirguis AA: Cholesterol-dependent human complement activation resulting in damage to liposomal model membranes. J Immunol 1977; 118: 342-347. (Pubitemid 8028549)
8. Seifert PS, Hugo F, Tranum-Jensen J, Zâhringer U, Muhly M, Bhakdi S: Isolation and characterization of a complement-activating lipid extracted from human atherosclerotic lesions. J Exp Med 1990; 172: 547-557. (Pubitemid 20248396)
9. Buono C, Come CE, Witztum JL, Maguire GF, Connelly PW, Carroll M, Lichtman AH: Influence of C3 deficiency on atherosclerosis. Circulation 2002; 105: 3025-3031. (Pubitemid 34693837)
10. Thorbjornsdottir P, Kolka R, Gunnarsson E, Bambir SH, Thorgeirsson G, Kotwal GJ, Arason GJ: Vaccinia virus complement control protein diminishes formation of atherosclerotic lesions: Complement is centrally involved in atherosclerotic disease. Ann NY Acad Sci 2005; 1056: 1-15. (Pubitemid 43030963)
11. Jha P, Kotwal GJ: Vaccinia complement control protein: Multi-functional protein and a potential wonder drug. J Biosci 2003; 28: 265-271. (Pubitemid 36512802)
12. Knowles JW, Maeda N: Genetic modifiers of atherosclerosis in mice. Arterioscler Thromb Vasc Biol 2000; 20: 2336-2345.
13. Getz GS, Reardon CA: Diet and murine atherosclerosis. Arterioscler Thromb Vasc Biol 2006; 26: 242-249. (Pubitemid 43732181)
14. Plump AS, Smith JD, Hayek T, Aalto-Setälä K, Walsh A, Verstuyft JG, Rubin EM, Breslow JL: Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 1992; 71: 343-353.
15. Zadelaar S, Kleemann R, Verschuren L, de Vries-Van der Weij J, van der Hoorn J, Princen HM, Kooistra T: Mouse models for atherosclerosis and pharmaceutical modifiers. Arterioscler Thromb Vasc Biol 2007; 27: 1706-1721. (Pubitemid 47207165)
16. Ishibashi S, Brown MS, Goldstein JL, Gerard RD, Hammer RE, Herz J: Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J Clin Invest 1993; 92: 883-893. (Pubitemid 23262411)
17. Williams H, Johnson JL, Carson KG, Jackson CL: Characteristics of intact and ruptured atherosclerotic plaques in brachiocephalic arteries of apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol 2002; 22: 788-792. (Pubitemid 34517790)
18. Virella G, Lopes-Virella MF: Infections and atherosclerosis. Transplant Proc 1987; 19(4 suppl 5):26-35. (Pubitemid 17151769)
19. Grayston JT: Chlamydia in atherosclerosis. Circulation 1993; 87: 1408-1409. (Pubitemid 23110413)
20. Deniset JF, Pierce GN: Possibilities for therapeutic interventions in disrupting Chlamydophila pneumoniae involvement in atherosclerosis. Fundam Clin Pharmacol 2010; 24: 607-617.
21. Kleemann R, Verschuren L, van Erk MJ, Nikolsky Y, Cnubben NH, Verheij ER, Smilde AK, Hendriks HF, Zadelaar S, Smith GJ, Kaznacheev V, Nikolskaya T, Melnikov A, Hurt-Camejo E, van der Greef J, van Ommen B, Kooistra T: Atherosclerosis and liver inflammation induced by increased dietary cholesterol intake: A combined transcriptomics and metabolomics analysis. Genome Biol 2007; 8:R200.
22. Recinos A 3rd, Carr BK, Bartos DB, Boldogh I, Carmical JR, Belalcazar LM, Brasier AR: Liver gene expression associated with diet and lesion development in atherosclerosisprone mice: Induction of components of alternative complement pathway. Physiol Genomics 2004; 19: 131-142. (Pubitemid 40039919)
23. Lewis RD, Jackson CL, Morgan BP, Hughes TR: The membrane attack complex of complement drives the progression of atherosclerosis in apolipoprotein E knockout mice. Mol Immunol 2010; 47: 1098-1105.
24. An G, Miwa T, Song WL, Lawson JA, Rader DJ, Zhang Y, Song WC: CD59 but not DAF deficiency accelerates atherosclerosis in female ApoE knockout mice. Mol Immunol 2009; 46: 1702-1709.
25. Wu G, Hu W, Shahsafaei A, Song W, Dobarro M, Sukhova GK, Bronson RR, Shi GP, Rother RP, Halperin JA, Qin X: Complement regulator CD59 protects against atherosclerosis by restricting the formation of complement membrane attack complex. Circ Res 2009; 104: 550-558.
26. Yun S, Leung VW, Botto M, Boyle JJ, Haskard DO: Brief report: Accelerated atherosclerosis in low-density lipoprotein receptordeficient mice lacking the membrane-bound complement regulator CD59. Arterioscler Thromb Vasc Biol 2008; 28: 1714-1716.
27. Matthijsen RA, de Winther MP, Kuipers D, van der Made I, Weber C, Herias MV, Gijbels MJ, Buurman WA: Macrophage-specific expression of mannose-binding lectin controls atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation 2009; 119: 2188-2195.
28. Bhatia VK, Yun S, Leung V, Grimsditch DC, Benson GM, Botto MB, Boyle JJ, Haskard DO: Complement C1q reduces early atherosclerosis in low-density lipoprotein receptordeficient mice. Am J Pathol 2007; 170: 416-426. (Pubitemid 47339218)
29. Leung VW, Yun S, Botto M, Mason JC, Malik TH, Song W, Paixao-Cavalcante D, Pickering MC, Boyle JJ, Haskard DO: Decay-accelerating factor suppresses complement C3 activation and retards atherosclerosis in lowdensity lipoprotein receptor-deficient mice. Am J Pathol 2009; 175: 1757-1767.
30. Lewis RD, Perry MJ, Guschina IA, Jackson CL, Morgan BP, Hughes TR: CD55 deficiency protects against atherosclerosis in ApoE deficient mice via C3a modulation of lipid metabolism. Am J Pathol 2011; 179: 1601-1607.
31. Yang X, Peterson L, Thieringer R, Deignan JL, Wang X, Zhu J, Wang S, Zhong H, Stepaniants S, Beaulaurier J, Wang IM, Rosa R, Cumiskey AM, Luo JM, Luo Q, Shah K, Xiao J, Nickle D, Plump A, Schadt EE, Lusis AJ, Lum PY: Identification and validation of genes affecting aortic lesions in mice. J Clin Invest 2010; 120: 2414-2422.
32. Malik TH, Cortini A, Carassiti D, Boyle JJ, Haskard DO, Botto M: The alternative pathway is critical for pathogenic complement activation in endotoxin-and diet-induced atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation 2010; 122: 1948-1956.
33. Persson L, Borén J, Robertson AK, Wallenius V, Hansson GK, Pekna M: Lack of complement factor C3, but not factor B, increases hyperlipidemia and atherosclerosis in apolipoprotein E-/-low-density lipoprotein receptor-/-mice. Arterioscler Thromb Vasc Biol 2004; 24: 1062-1067. (Pubitemid 38737832)
34. Speidl WS, Kastl SP, Huber K, Wojta J: Complement in atherosclerosis -friend or foe? J Thromb Haemost 2011; 9: 428-440.
35. Patel S, Thelander EM, Hernandez M, Montenegro J, Hassing H, Burton C, Mundt S, Hermanowski-Vosatka A, Wright SD, Chao YS, Detmers PA: ApoE(-/-) mice develop atherosclerosis in the absence of complement component C5. Biochem Biophys Res Commun 2001; 286: 164-170. (Pubitemid 32917664)
36. Chou MY, Fogelstrand L, Hartvigsen K, Hansen LF, Woelkers D, Shaw PX, Choi J, Perkmann T, Bäckhed F, Miller YI, Hörkkö S, Corr M, Witztum JL, Binder CJ: Oxidation-specific epitopes are dominant targets of innate natural antibodies in mice and humans. J Clin Invest 2009; 119: 1335-1349.
37. Lewis MJ, Malik TH, Ehrenstein MR, Boyle JJ, Botto M, Haskard DO: Immunoglobulin M is required for protection against atherosclerosis in low-density lipoprotein receptordeficient mice. Circulation 2009; 120: 417-426.
38. Shaw PX, Hörkkö S, Chang MK, Curtiss LK, Palinski W, Silverman GJ, Witztum JL: Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity. J Clin Invest 2000; 105: 1731-1740. (Pubitemid 30421754)
39. Stanic AK, Stein CM, Morgan AC, Fazio S, Linton MF, Wakeland EK, Olsen NJ, Major AS: Immune dysregulation accelerates atherosclerosis and modulates plaque composition in systemic lupus erythematosus. Proc Natl Acad Sci USA 2006; 103: 7018-7023.
40. Wetsel RA, Kildsgaard J, Zsigmond E, Liao W, Chan L: Genetic deficiency of acylation stimulating protein (ASP(C3ades-Arg)) does not cause hyperapobetalipoproteinemia in mice. J Biol Chem 1999; 274: 19429-19433.
41. Murray I, Sniderman AD, Cianflone K: Mice lacking acylation stimulating protein (ASP) have delayed postprandial triglyceride clearance. J Lipid Res 1999; 40: 1671-1676. (Pubitemid 29418708)
42. Murray I, Sniderman AD, Havel PJ, Cianflone K: Acylation stimulating protein (ASP) deficiency alters postprandial and adipose tissue metabolism in male mice. J Biol Chem 1999; 274: 36219-36225.
43. Teupser D, Persky AD, Breslow JL: Induction of atherosclerosis by low-fat, semisynthetic diets in LDL receptor-deficient C57BL/6J and FVB/NJ mice: Comparison of lesions of the aortic root, brachiocephalic artery, and whole aorta (en face measurement). Arterioscler Thromb Vasc Biol 2003; 23: 1907-1913. (Pubitemid 37254883)
44. Bjerketorp J, Nilsson M, Ljungh A, Flock JI, Jacobsson K, Frykberg L: A novel von Willebrand factor binding protein expressed by Staphylococcus aureus. Microbiology 2002; 148: 2037-2044. (Pubitemid 34785288)
45. Ananyeva NM, Kouiavskaia DV, Shima M, Saenko EL: Intrinsic pathway of blood coagulation contributes to thrombogenicity of atherosclerotic plaque. Blood 2002; 99: 4475-4485. (Pubitemid 34627217)
46. Breitenstein A, Tanner FC, Luscher TF: Tissue factor and cardiovascular disease: Quo vadis? Circ J 2010; 74: 3-12.
47. Ikeda K, Nagasawa K, Horiuchi T, Tsuru T, Nishizaka H, Niho Y: C5a induces tissue factor activity on endothelial cells. Thromb Haemost 1997; 77: 394-398. (Pubitemid 27084936)
48. Massberg S, Brand K, Grüner S, Page S, Müller E, Müller I, Bergmeier W, Richter T, Lorenz M, Konrad I, Nieswandt B, Gawaz M: A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation. J Exp Med 2002; 196: 887-896.
49. Yin W, Ghebrehiwet B, Peerschke EI: Expression of complement components and inhibitors on platelet microparticles. Platelets 2008; 19: 225-233. (Pubitemid 351574446)
50. Del Conde I, Crúz MA, Zhang H, López JA, Afshar-Kharghan V: Platelet activation leads to activation and propagation of the complement system. J Exp Med 2005; 201: 871-879. (Pubitemid 40524457)
51. Berg AH, Scherer PE: Adipose tissue, inflammation, and cardiovascular disease. Circ Res 2005; 96: 939-949. (Pubitemid 40712793)
52. Alexaki VI, Notas G, Pelekanou V, Kampa M, Valkanou M, Theodoropoulos P, Stathopoulos EN, Tsapis A, Castanas E: Adipocytes as immune cells: Differential expression of TWEAK, BAFF, and APRIL and their receptors (Fn14, BAFF-R, TACI, and BCMA) at different stages of normal and pathological adipose tissue development. J Immunol 2009; 183: 5948-5956.
53. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A, Ross JS, Tartaglia LA, Chen H: Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003; 112: 1821-1830. (Pubitemid 38063705)
54. Fain JN, Madan AK, Hiler ML, Cheema P, Bahouth SW: Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology 2004; 145: 2273-2282. (Pubitemid 38535056)
55. MacLaren RE, Cui W, Lu H, Simard S, Cianflone K: Association of adipocyte genes with ASP expression: A microarray analysis of subcutaneous and omental adipose tissue in morbidly obese subjects. BMC Med Genomics 2010; 3: 3.
56. Kougias P, Chai H, Lin PH, Yao Q, Lumsden AB, Chen C: Effects of adipocyte-derived cytokines on endothelial functions: Implication of vascular disease. J Surg Res 2005; 126: 121-129. (Pubitemid 40726256)
57. Spencer M, Yao-Borengasser A, Unal R, Rasouli N, Gurley CM, Zhu B, Peterson CA, Kern PA: Adipose tissue macrophages in insulin resistant subjects are associated with collagen VI, fibrosis and demonstrate alternative activation. Am J Physiol Endocrinol Metab 2010; 299:E1016-E1027.
58. Chudek J, Wiecek A: Adipose tissue, inflammation and endothelial dysfunction. Pharmacol Rep 2006; 58(suppl):81-88.
59. Peake P, Shen Y: Factor H binds to the Nterminus of adiponectin and modulates complement activation. Biochem Biophys Res Commun 2010; 397: 361-366.
60. Liu J, Divoux A, Sun J, Zhang J, Clément K, Glickman JN, Sukhova GK, Wolters PJ, Du J, Gorgun CZ, Doria A, Libby P, Blumberg RS, Kahn BB, Hotamisligil GS, Shi GP: Genetic deficiency and pharmacological stabilization of mast cells reduce diet-induced obesity and diabetes in mice. Nat Med 2009; 15: 940-945.
61. Pattrick M, Luckett J, Yue L, Stover C: Dual role of complement in adipose tissue. Mol Immunol 2009; 46: 755-760.
62. Platt KA, Min HY, Ross SR, Spiegelman BM: Obesity-linked regulation of the adipsin gene promoter in transgenic mice. Proc Natl Acad Sci USA 1989; 86: 7490-7494. (Pubitemid 19254482)
63. Henrichot E, Juge-Aubry CE, Pernin A, Pache JC, Velebit V, Dayer JM, Meda P, Chizzolini C, Meier CA: Production of chemokines by perivascular adipose tissue: A role in the pathogenesis of atherosclerosis? Arterioscler Thromb Vasc Biol 2005; 25: 2594-2599. (Pubitemid 43732284)
64. Police SB, Thatcher SE, Charnigo R, Daugherty A, Cassis LA: Obesity promotes inflammation in periaortic adipose tissue and angiotensin II-induced abdominal aortic aneurysm formation. Arterioscler Thromb Vasc Biol 2009; 29: 1458-1464.
65. Chavez-Sanchez L, Madrid-Miller A, Chávez-Rueda K, Legorreta-Haquet MV, Tesoro-Cruz E, Blanco-Favela F: Activation of TLR2 and TLR4 by minimally modified low-density lipoprotein in human macrophages and monocytes triggers the inflammatory response. Hum Immunol 2010; 71: 737-744.
66. Speidl WS, Kastl SP, Hutter R, Katsaros KM, Kaun C, Bauriedel G, Maurer G, Huber K, Badimon JJ, Wojta J: The complement component C5a is present in human coronary lesions in vivo and induces the expression of MMP-1 and MMP-9 in human macrophages in vitro. FASEB J 2011; 25: 35-44.
67. Manthey HD, Woodruff TM, Taylor SM, Monk PN: Complement component 5a (C5a). Int J Biochem Cell Biol 2009; 41: 2114-2117.
68. Verschuren L, Kooistra T, Bernhagen J, Voshol PJ, Ouwens DM, van Erk M, de Vriesvan der Weij J, Leng L, van Bockel JH, van Dijk KW, Fingerle-Rowson G, Bucala R, Kleemann R: MIF deficiency reduces chronic inflammation in white adipose tissue and impairs the development of insulin resistance, glucose intolerance, and associated atherosclerotic disease. Circ Res 2009; 105: 99-107.
69. Mamane Y, Chung Chan C, Lavallee G, Morin N, Xu LJ, Huang J, Gordon R, Thomas W, Lamb J, Schadt EE, Kennedy BP, Mancini JA: The C3a anaphylatoxin receptor is a key mediator of insulin resistance and functions by modulating adipose tissue macrophage infiltration and activation. Diabetes 2009; 58: 2006-2017.
70. Fujisaka S, Usui I, Bukhari A, Ikutani M, Oya T, Kanatani Y, Tsuneyama K, Nagai Y, Takatsu K, Urakaze M, Kobayashi M, Tobe K: Regulatory mechanisms for adipose tissue M1 and M2 macrophages in diet-induced obese mice. Diabetes 2009; 58: 2574-2582.
71. Shaul ME, Bennett G, Strissel KJ, Greenberg AS, Obin MS: Dynamic, M2-like remodeling phenotypes of CD11c+ adipose tissue macrophages during high-fat diet-induced obesity in mice. Diabetes 2010; 59: 1171-1181.
72. Havel PJ: Update on adipocyte hormones: Regulation of energy balance and carbohydrate/ lipid metabolism. Diabetes 2004; 53 (suppl 1):S143-S151. (Pubitemid 38168707)
73. Lötzer K, Döpping S, Connert S, Gräbner R, Spanbroek R, Lemser B, Beer M, Hildner M, Hehlgans T, van der Wall M, Mebius RE, Lovas A, Randolph GJ, Weih F, Habenicht AJ: Mouse aorta smooth muscle cells differentiate into lymphoid tissue organizer-like cells on combined tumor necrosis factor receptor-1/lymphotoxin beta-receptor NF-kappaB signaling. Arterioscler Thromb Vasc Biol 2010; 30: 395-402.
74. Sumiyoshi K, Mokuno H, Iesaki T, Shimada K, Miyazaki T, Kume A, Kiyanagi T, Kuremoto K, Watanabe Y, Tada N, Daida H: Deletion of the Fc receptors gamma chain preserves endothelial function affected by hypercholesterolaemia in mice fed on a high-fat diet. Cardiovasc Res 2008; 80: 463-470.
75. Zhao M, Wigren M, Dunér P, Kolbus D, Olofsson KE, Björkbacka H, Nilsson J, Fredrikson GN: FcgammaRIIB inhibits the development of atherosclerosis in low-density lipoprotein receptor-deficient mice. J Immunol 2010; 184: 2253-2260.
76. Shushakova N, Skokowa J, Schulman J, Baumann U, Zwirner J, Schmidt RE, Gessner JE: C5a anaphylatoxin is a major regulator of activating versus inhibitory FcgammaRs in immune complex-induced lung disease. J Clin Invest 2002; 110: 1823-1830. (Pubitemid 36076489)
77. Mold C, Rodic-Polic B, Du Clos TW: Protection from Streptococcus pneumoniae infection by C-reactive protein and natural antibody requires complement but not Fc gamma receptors. J Immunol 2002; 168: 6375-6381. (Pubitemid 34620061)
78. Leon F, Contractor N, Fuss I, Marth T, Lahey E, Iwaki S, la Sala A, Hoffmann V, Strober W, Kelsall BL: Antibodies to complement receptor 3 treat established inflammation in murine models of colitis and a novel model of psoriasiform dermatitis. J Immunol 2006; 177: 6974-6982. (Pubitemid 44715063)
79. Soruri A, Riggert J, Schlott T, Kiafard Z, Dettmer C, Zwirner J: Anaphylatoxin C5a induces monocyte recruitment and differentiation into dendritic cells by TNF-alpha and prostaglandin E2-dependent mechanisms. J Immunol 2003; 171: 2631-2636. (Pubitemid 37025576)
80. Fang C, Zhang X, Miwa T, Song WC: Complement promotes the development of inflammatory T-helper 17 cells through synergistic interaction with Toll-like receptor signaling and interleukin-6 production. Blood 2009; 114: 1005-1015.
81. Gao Q, Jiang Y, Ma T, Zhu F, Gao F, Zhang P, Guo C, Wang Q, Wang X, Ma C, Zhang Y, Chen W, Zhang L: A critical function of Th17 proinflammatory cells in the development of atherosclerotic plaque in mice. J Immunol 2010; 185: 5820-5827.
82. Woodruff TM, Nandakumar KS, Tedesco F: Inhibiting the C5-C5a receptor axis. Mol Immunol 2011; 48: 1631-1642.
83. Manthey HD, Thomas AC, Shiels IA, Zernecke A, Woodruff TM, Rolfe B, Taylor SM: Complement C5a inhibition reduces atherosclerosis in ApoE-/-mice. FASEB J 2011; 25: 2447-2455.
84. Széplaki G, Varga L, Füst G, Prohászka Z: Role of complement in the pathomechanism of atherosclerotic vascular diseases. Mol Immunol 2009; 46: 2784-2793.
85. Langer HF, Chung KJ, Orlova VV, Choi EY, Kaul S, Kruhlak MJ, Alatsatianos M, Deangelis RA, Roche PA, Magotti P, Li X, Economopoulou M, Rafail S, Lambris JD, Chavakis T: Complement-mediated inhibition of neovascularization reveals a point of convergence between innate immunity and angiogenesis. Blood 2010; 116: 4395-4403.
86. Bongrazio M, Pries AR, Zakrzewicz A: The endothelium as physiological source of properdin: Role of wall shear stress. Mol Immunol 2003; 39: 669-675. (Pubitemid 35454079)
87. Vachharajani V, Granger DN: Adipose tissue: A motor for the inflammation associated with obesity. IUBMB Life 2009; 61: 424-430.
88. Rutkowski B, Szolkiewicz M, Korczynska J, Sucajtys E, Stelmanska E, Nieweglowski T, Swierczynski J: The role of lipogenesis in the development of uremic hyperlipidemia. Am J Kidney Dis 2003; 41(3 suppl 1):S84-S88. (Pubitemid 36278353)